204 related articles for article (PubMed ID: 11520816)
21. Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth.
Gutman D; Epstein-Barash H; Tsuriel M; Golomb G
Adv Exp Med Biol; 2012; 733():165-79. PubMed ID: 22101722
[TBL] [Abstract][Full Text] [Related]
22. Structural features of nonpeptide prenyl pyrophosphates that determine their antigenicity for human gamma delta T cells.
Morita CT; Lee HK; Wang H; Li H; Mariuzza RA; Tanaka Y
J Immunol; 2001 Jul; 167(1):36-41. PubMed ID: 11418629
[TBL] [Abstract][Full Text] [Related]
23. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Reszka AA; Halasy-Nagy JM; Masarachia PJ; Rodan GA
J Biol Chem; 1999 Dec; 274(49):34967-73. PubMed ID: 10574973
[TBL] [Abstract][Full Text] [Related]
25. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
[TBL] [Abstract][Full Text] [Related]
26. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
Front Immunol; 2021; 12():654080. PubMed ID: 34040604
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
28. Essential contribution of germline-encoded lysine residues in Jgamma1.2 segment to the recognition of nonpeptide antigens by human gammadelta T cells.
Miyagawa F; Tanaka Y; Yamashita S; Mikami B; Danno K; Uehara M; Minato N
J Immunol; 2001 Dec; 167(12):6773-9. PubMed ID: 11739492
[TBL] [Abstract][Full Text] [Related]
29. Use of bisphosphonates in cancer patients.
Body JJ; Coleman RE; Piccart M
Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
[No Abstract] [Full Text] [Related]
30. Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.
Puan KJ; Low JS; Tan TW; Wee JT; Tan EH; Fong KW; Chua ET; Jin C; Giner JL; Morita CT; Goh CH; Hui KM
Cancer Immunol Immunother; 2009 Jul; 58(7):1095-107. PubMed ID: 19043708
[TBL] [Abstract][Full Text] [Related]
31. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
Kwak HB; Kim JY; Kim KJ; Choi MK; Kim JJ; Kim KM; Shin YI; Lee MS; Kim HS; Kim JW; Chun CH; Cho HJ; Hong GY; Juhng SK; Yoon KH; Park BH; Bae JM; Han JK; Oh J
Biol Pharm Bull; 2009 Jul; 32(7):1193-8. PubMed ID: 19571384
[TBL] [Abstract][Full Text] [Related]
32. Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs.
Wang H; Fang Z; Morita CT
J Immunol; 2010 Jun; 184(11):6209-22. PubMed ID: 20483784
[TBL] [Abstract][Full Text] [Related]
33. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.
Kato Y; Tanaka Y; Miyagawa F; Yamashita S; Minato N
J Immunol; 2001 Nov; 167(9):5092-8. PubMed ID: 11673519
[TBL] [Abstract][Full Text] [Related]
34. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
35. Perforin-dependent killing of tumor cells by Vgamma1Vdelta1-bearing T-cells.
Narazaki H; Watari E; Shimizu M; Owaki A; Das H; Fukunaga Y; Takahashi H; Sugita M
Immunol Lett; 2003 Mar; 86(1):113-9. PubMed ID: 12600753
[TBL] [Abstract][Full Text] [Related]
36. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells.
Knight A; Mackinnon S; Lowdell MW
Cytotherapy; 2012 Oct; 14(9):1110-8. PubMed ID: 22800570
[TBL] [Abstract][Full Text] [Related]
37. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
38. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.
Lichtenberger LM; Romero JJ; Gibson GW; Blank MA
Dig Dis Sci; 2000 Sep; 45(9):1792-801. PubMed ID: 11052322
[TBL] [Abstract][Full Text] [Related]
39. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.
Choudhary A; Davodeau F; Moreau A; Peyrat MA; Bonneville M; Jotereau F
J Immunol; 1995 Apr; 154(8):3932-40. PubMed ID: 7706731
[TBL] [Abstract][Full Text] [Related]
40. Human gamma delta T cells and tumor immunotherapy.
Tanaka Y
J Clin Exp Hematop; 2006 Mar; 46(1):11-23. PubMed ID: 17058804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
